tbuckley/cabot-search huggingface dataset:
THU0770-HPR Cost savings by favouring infliximab biosimilars in the eastern region of austria
Authors: B Reichardt, G Reiter, T Stamm, V Nell-Duxneuner
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> Since April 2015, the availability of Infliximab biosimilars offered a new potential for cost savings in limited financial resources of the healthcare system. In Austria, there is currently no open tendering for drugs dispensed at charge of sickness funds and biosimilars take a long time to gain an appreciable market share overall. A contract made between the public hospital operator and the regionale sickness fund of the Eastern Austrian county Burgenland (BGKK) offered a new opportunity regarding the interface problems due to the dually financed (inpatient and outpatient care is separately financed in Austria) health system. Only outpatient care is covered by regional sickness funds. <h3>Methods</h3> With reference to the NOR-SWITCH study (1), confirming the interchangeability of the branded Infiximab and infliximab biosimilar, and the large price advantage of the latter, the BGKK agreed as an exception in the Austrian health system on direct reimbursement of infliximab to the public hospital operator (inpatient care). The cost savings were calculated based on the monthly invoices of the hospitals. Instead of € 477.19 for 100 mg of branded infliximab, the price for biosimilar infliximab does not exceed € 300.–. The 23 patients on biosimilar were infused with 9,400 mg infliximab overall. <h3>Results</h3> After signing the agreement in December 2016, 23 consecutive patients, representing 82% of all patients on infliximab in Eastern Austrian county Burgenland, switched to or were incident users of an infliximab biosimilar, the 18% have not yet switched due to remaining stocks of branded infliximab or were adolescents where switching is not forced because of lacking data. According to the individual dosing and a price benefit of about 37%, monthly cost savings of about € 16,650.00 could be generated. <h3>Conclusions</h3> Despite availability of cost-effective infliximab biosimilars in Austria, the drugs did not gain significant market share, in contrast to the Scandinavian healthcare systems, &lt;4% vs. &gt;90% in the first half year of 2016. Further research is needed including clinical data to strengthen the results of this pilot study. <h3>References</h3> Jørgensen, K. et al. Biosimilar infliximab is not inferior to originator infliximab: Results from the 52-week randomized NOR-SWITCH trial. United European Gastroenterology Week 2016; LB15. <h3>Disclosure of Interest</h3> None declared
植物におけるイソプレノイド発電システム‐生合成プロセスへのメバロン酸とメチルエリスリトールりん酸経路の寄与をどのようにして評価する携帯ツールボックス【Powered by NICT】
Authors: Lipko Agata, Swiezewska Ewa
Journal: Progress in Lipid Research (2016)
Chronic Myocardial Infarction
Authors: Diego Goldwasser, Marcelo V. Elizari, Antonio Bayés de Luna
Journal: Circulation (2017)

ECG CHALLENGEThis ECG was recorded during a routine checkup of a 77-year-old man who had a heart attack 8 months earlier.He was in the countryside when he felt constrictive chest pain lasting ≈2 hours but was not hospitalized until 20 hours later.A coronary angiogram was performed the following day.Based on ECG demonstrated in Figure 1, where is the culprit lesion?Where was the myocardial infarction (MI) located?Please turn the page to read the diagnosis.
Neodymium-doped yttrium aluminium garnet laser to treat primary pilonidal cysts: an alternative treatment
Authors: M.J. Suárez Valladares, M.A. Rodríguez Prieto
Journal: British Journal of Dermatology (2017)

A pilonidal cyst is an acquired inflammatory disease that affects young adults. Many treatments have been described, although no clear consensus has been reported. At present, surgical intervention is the first line of treatment. The main problem after treatment is the high recurrence of the pilonidal sinus (PNS).

We treated six patients with clinical PNS in the natal cleft (with different time of evolution) and 1.5 cm diameter approximately with Nd:YAG (1064nm). It took 3-4 treatments to resolve the sinus. It is important to remove the residual hairs into the cyst. All of our patients healed. Six lesions were eradicated, and no symptoms were described after the treatment. The mean follow-up period was 52 months (12 to 100 months) without any recurrences.

The early management of pilonidal cysts, with Nd:YAG (1064nm) could be an interesting way of treatment versus conventional surgery, because it causes few side effects and the clinical and aesthetic results are optimal.

This article is protected by copyright. All rights reserved.
Radical Surgery for Gastric Cancer
Authors: Alexander Brunschwig
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Radical Surgery for Gastric Cancer Get access Alexander Brunschwig Alexander Brunschwig professor of surgery Department of Surgery, University of Chicago Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 5, April 1945, Pages 365–366, https://doi.org/10.1093/jnci/5.5.365 Published: 01 April 1945
げっ歯類の完全な厚さの腹壁欠損における経時的生物由来の外科用メッシュの分解と機械的強度【Powered by NICT】
Authors: A Costa, J D Naranjo, N J Turner, I T Swinehart, B D Kolich, S A Shaffiey, R Londono, T J Keane, J E Reing, S A Johnson, S F Badylak
Journal: Biomaterials (2016)
Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands
Authors: Susanne M A J Tielemans, Hester E de Melker, Susan J M Hahné, Anna G C Boef, Fiona R M van der Klis, Elisabeth A M Sanders, Marianne A B van der Sande, Mirjam J Knol
Journal: BMJ (2017)

<b>Objectives</b>&nbsp;To investigate whether measles, mumps, and rubella (MMR) vaccine has positive non-specific effects in a high income setting and to compare rates of hospital admissions for infections between children aged ≤2 years who received live MMR vaccine and those who received an inactivated vaccine against diphtheria, tetanus, pertussis, polio, and <i>Haemophilus influenzae</i> type b (DTaP-IPV-Hib) as their most recent vaccination. <b>Design</b>&nbsp;Nationwide population based cohort study. <b>Setting</b>&nbsp;In the Netherlands, DTaP-IPV-Hib+pneumococcal vaccination (PCV) is recommended at ages 2, 3, 4, and 11 months and MMR + meningococcal C (MenC) vaccination at age 14 months. Data from the national vaccine register were linked to hospital admission data. <b>Participants</b>&nbsp;1 096 594 children born in 2005-11 who received the first four DTaP-IPV-Hib+PCV vaccines. <b>Main outcome measures</b>&nbsp;Hazard ratio for admission to hospital for infection in children with MMR+MenC compared with the fourth DTaP-IPV-Hib+PCV as their most recent vaccination. Cox regression was performed with most recent vaccination as time dependent variable, adjusted for potential confounders. Analyses were repeated with admission for injuries or poisoning as a negative control outcome. In addition, rate of admission for infection was compared between the fourth and third DTaP-IPV-Hib+PCV<b></b>as most recent vaccination. <b>Results</b>&nbsp;Having had MMR+MenC as the most recent vaccination was associated with a hazard ratio of 0.62 (95% confidence interval 0.57 to 0.67) for admission to hospital for infection and 0.84 (0.73 to 0.96) for injuries or poisoning, compared with the fourth DTaP-IPV-Hib+PCV as most recent vaccination. The fourth DTaP-IPV-Hib+PCV as most recent vaccination was associated with a hazard ratio of 0.69 (0.63 to 0.76) for admission to hospital for infection, compared with the third DTaP-IPV-Hib+PCV as most recent vaccination. <b>Conclusions</b>&nbsp;Healthy vaccinee bias could at least partly explain the observed lower rate of admission to hospital with infection after MMR vaccination. The lower rate is associated with receipt of any additional vaccine, not specifically MMR vaccine. This emphasises the caution required in the interpretation of findings from observational studies on non-specific effects of vaccination.
Abstract #711: Local radiotherapy suppresses granulocyte colony-stimulating factor induced tumor angiogenesis and metastasis
Authors: Pu-Yuan Chang, Li-Mei Lin, Helen Chen, Chuan-Kai Chou, Hui-Ju Ch'ang
Journal: Cancer Research (2009)

Purpose: G-CSF (Granulocyte Colony-Stimulating Factor) is commonly used in cancer patients to ameliorate neutropenia and to prevent severe infections. Many recent preclinical studies reveal tumor promoting and stem cell mobilizing effect of G-CSF. Because of severe toxicity, it is suggested that G-CSF should be avoided during concomitant chemoradiotherapy. The safety of G-CSF in cancer treatment especially during radiotherapy should be re-evaluated. Materials and Methods: To evaluate tumor promoting and mobilizing effect of G-CSF with or without local radiation, tumor growth delay and lung colony assay of B16F10 melanoma and Lewis lung carcinoma cells were established. Direct effect of G-CSF on cells was evaluated by in vitro proliferating, wound-healing and trans-well migration assay. In vivo effect of G-CSF was evaluated by histology studies. The role of bone marrow (BM) stem cells in tumor growth and metastasis was studied by subcutaneous tumor implant in chimeric mice, established 4 weeks after BM transplantation from green fluorescence protein (GFP) transgenic mice. GFP labeled BM cells in tumors and organs were evaluated by flow cytometry and immunohistochemistry. Results: High dose long duration of G-CSF enhanced local tumor growth with increased tumor vessel density in both tumor models. The promoting effect was suppressed when G-CSF was given along with radiation. G-CSF did not enhance tumor or stromal cell proliferation directly but recruited BM cells to tumor site. After local radiation, the amount of BM cells recruited by G-CSF to tumor site decreased. This phenomenon is associated with decreased microvessel density in tumors. The incidence of lung metastasis was increased by both local radiation and G-CSF treatment. But there was no additive effect between G-CSF and radiation on tumor metastasis. G-CSF enhanced tumor cell motility and increased BM cell recruitment to normal lung. When combined with local radiation, tumor cell motility was not further enhanced, neither the amount of BM cell mobilized to lung. Conclusion: Administration of G-CSF is safe during local radiotherapy. Concomitant G-CSF and radiation may not promote local tumor growth or distant metastasis.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 711.
Going With the Flow: The Promise and Challenge of Liquid Biopsies
Authors: M.J. Friedrich
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evolocumab “must become cheaper” to be cost effective in enhancing benefits of statins
Authors: Nigel Hawkes
Journal: BMJ (2017)

Evolocumab, a cholesterol lowering drug that may enhance the benefits of statins, will need to be sold at a much lower price to be cost effective, two studies have found, but they disagree on how deep this price cut would need to be.

A team led by Dhruv Kazi, of Zuckerberg San Francisco Hospital in California, USA, found that the listed price for evolocumab (Repatha) would need to be reduced by more than two thirds to meet a cost effectiveness threshold of $100 000 (£77 300; €83 200) per quality adjusted life year (QALY). Evolocumab, made by Amgen, has a US list price of more than $14 000 a year—but a price no greater than $4215 a year would be required …
遺伝子型推定:遺伝子型推定のための64,976のハプロタイプの参照パネル
Authors: Mccarthy Shane, Luo Yang, Gilly Arthur, Barrett Jeffrey C, Zeggini Eleftheria, Soranzo Nicole, Walter Klaudia, Anderson Carl A, Durbin Richard, Das Sayantan, Kang Hyun Min, Fuchsberger Christian, Kwong Alan, Scott Laura J, Chen Sai, Boehnke Michael, Abecasis Goncalo, Kretzschmar Warren, Mahajan Anubha, Mccarthy Mark I, Marchini Jonathan, Delaneau Olivier, Wood Andrew R, Tuke Marcus, Frayling Timothy, Teumer Alexander, Nauck Matthias, Danecek Petr, Sharp Kevin, Sidore Carlo, Angius Andrea, Busonero Fabio, Cucca Francesco, Timpson Nicholas, Corbin Laura J, Smith George Davey, Min Josine L, Koskinen Seppo, Salomaa Veikko, Vrieze Scott, Zhang He, Willer Cristen, Veldink Jan, Van Den Berg Leonard H, Van Rheenen Wouter, Dekker Annelot, Peters Ulrike, Harrison Tabitha, Kooperberg Charles, Pato Carlos, Pato Michele, Van Duijn Cornelia M, Gillies Christopher E, Sampson Matthew G, Gandin Ilaria, Cocca Massimiliano, Pirastu Nicola, Gasparini Paolo, Mezzavilla Massimo, Traglia Michela, Sala Cinzia, Toniolo Daniela, Boomsma Dorrett, Branham Kari, Breen Gerome, Brummett Chad M, Fraser Ross M, Campbell Harry, Wilson James F, Chan Andrew, Kretzler Matthias, Chew Emily, Collins Francis S, Dedoussis George, Farmaki Aliki‐Eleni, Dorr Marcus, Volker Uwe, Ferrucci Luigi, Forer Lukas, Schoenherr Sebastian, Gabriel Stacey, Palotie Aarno, Altshuler David, Levy Shawn, Myers Richard M, Groop Leif, Hattersley Andrew, Holmen Oddgeir L, Hveem Kristian, Lee James C, Mcgue Matt, Iacono William, Meitinger Thomas, Melzer David, Mohlke Karen L, Vincent John B, Nickerson Deborah, Mcinnis Melvin, Richards J Brent, Small Kerrin, Spector Timothy, Schlessinger David
Journal: Nature Genetics (2016)
Prosapip1-Dependent Synaptic Adaptations in the Nucleus Accumbens Drive Alcohol Intake, Seeking, and Reward
Authors: Sophie Laguesse, Nadege Morisot, Jung Hoon Shin, Feng Liu, Martin F. Adrover, Samuel A. Sakhai, Marcelo F. Lopez, Khanhky Phamluong, William C. Griffin, Howard C. Becker, Kevin J. Bender, Veronica A. Alvarez, Dorit Ron
Journal: Neuron (2017)
Erratum: Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis (Journal of the American Society of Nephrology (July 2000))
Authors: A. H. Moss, Jr Owen, R. Albert, E. Brewer, H. Danko, J. H. Galla, R. M. Hendrickson, A. R. Jonsen, J. Kari, B. Kasiske, K. King, J. Kitsen, J. M. Newmann, C. A. Price, R. Rettig, D. Singer
Journal: Journal of the American Society of Nephrology (2000)
腫瘍微粒子の術前注入はリソソーム経路を通した非筋肉浸潤性膀胱癌の膀胱内化学療法を増強する【Powered by NICT】
Authors: Jin Xun, Ma Jingwei, Liang Xiaoyu, Tang Ke, Liu Yuying, Yin Xiaonan, Zhang Yi, Zhang Huafeng, Xu Pingwei, Chen Degao, Zhang Tianzhen, Lu Jinzhi, Hu Zhuowei, Qin Xiaofeng, Zeng Xiaoyong, Li Longcheng, Huang Bo
Journal: Biomaterials (2017)
NHS needs extra £350m to cope this winter, service providers say
Authors: Ingrid Torjesen
Journal: BMJ (2017)

The NHS will need an emergency cash injection of between £200m (€220m; $260m) and £350m to manage demand from patients this winter, says NHS Providers, the organisation that represents 97% of hospital, mental health, community care, and ambulance trusts in England.

Without this extra investment waiting times will lengthen, especially in hospital emergency departments, jeopardising patients’ safety, because trusts do not have the capacity to meet extra expected demand, NHS Providers say in a new report.1 The report assesses the preparedness of providers to cope this winter, informed by input from system leaders and frontline staff and the latest performance data.

This winter is predicted …
Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results
Authors: Dae Hyun Kim, Hajime Uno, Lee-Jen Wei
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 11360: Pulmonary Vein-Dominant Structural Remodeling in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation
Authors: Kentaro Yoshida, Hidekazu Tsuneoka, Yasuaki Tsumagari, Kazutaka Aonuma
Journal: Circulation (2016)

Introduction: Atrial fibrillation (AF) is prevalent in patients with hypertrophic cardiomyopathy (HCM). However, structural remodeling of the left atrium (LA) and pulmonary veins (PV) has rarely been investigated in this setting. This study aimed to identify differences in LA and PV remodeling between HCM and hypertensive heart disease (HHD) using 3D-CT. Methods: Included in this study are 33 patients with HCM, 25 patients with HHD, and 29 patients without any co-morbidities who were referred for catheter ablation of AF. ANP and BNP levels before ablation and Troponin T level after ablation were measured, and LA and PV diameters were 3-dimensionally determined. Results: LA diameters in the control group was shorter than that in the HHD or HCM group (Fig 1). The PV diameters were the longest in the HCM group (Fig 2). The PV/LA ratio was higher in the HCM group than the control or HHD group (PV-dominant remodeling) (Fig 3). All biomarkers were the highest in the HCM group (Fig 4). Conclusions: The stiff LA caused from atrial hypertrophy may account for higher levels of biomarkers and PV-dominant remodeling in HCM.
慢性骨髄性白血病においてキナーゼ不活性でありチロシンキナーゼ阻害剤耐性の一因とはならないBCR-ABL35INS挿入/切断型変異体
Authors: O’Hare Thomas, S Zabriskie Matthew, A Eide Christopher, Agarwal Anupriya, T Adrian Lauren, You Huihong, S Corbin Amie, Yang Fei, D Press Richard, M Rivera Victor, Toplin Julie, Wong Stephane, W Deininger Michael, J Druker Brian
Journal: Blood (2011)
FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB–BMP Signaling Cross-talk
Authors: Marco Chi-Chung Lau, Kai Yu Ng, Tin Lok Wong, Man Tong, Terence K. Lee, Xiao-Yan Ming, Simon Law, Nikki P. Lee, Annie L. Cheung, Yan-Ru Qin, Kwok Wah Chan, Wen Ning, Xin-Yuan Guan, Stephanie Ma
Journal: Cancer Research (2017)

Esophageal squamous cell carcinoma (ESCC) has a generally poor prognosis, and molecular markers to improve early detection and predict outcomes are greatly needed. Here, we report that the BMP-binding follistatin-like protein FSTL1 is overexpressed in ESCCs, where it correlates with poor overall survival. Genetic amplification of FSTL1 or chromosome 3q, where it is located, occurred frequently in ESCC, where FSTL1 copy number correlated positively with higher FSTL1 protein expression. Elevating FSTL1 levels by various means was sufficient to drive ESCC cell proliferation, clonogenicity, migration, invasion, self-renewal, and cisplatin resistance in vitro and tumorigenicity and distant metastasis in vivo Conversely, FSTL1 attenuation by shRNA or neutralizing antibody elicited the opposite effects in ESCC cells. mRNA profiling analyses suggested that FSTL1 drives ESCC oncogenesis and metastasis through various pathways, with deregulation of NFκB and BMP signaling figuring prominently. Cross-talk between the NFκB and BMP pathways was evidenced by functional rescue experiments using inhibitors of NFκB and TLR4. Our results establish the significance of FSTL1 in driving oncogenesis and metastasis in ESCC by coordinating NFκB and BMP pathway control, with implications for its potential use as a diagnostic or prognostic biomarker and as a candidate therapeutic target in this disease setting. Cancer Res; 77(21); 5886-99. ©2017 AACR.
<i>Notes from the Field</i>: Fatal Yellow Fever in a Traveler Returning From Peru — New York, 2016
Authors: Alexandra P. Newman, Rebecca Becraft, Amy B. Dean, Rene Hull, Bryon Backenson, Gillian Hale, Janeen Laven, Julu Bhatnagar, J. Erin Staples
Journal: MMWR Morbidity and Mortality Weekly Report (2017)
Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis
Authors: Ying Wei, Thomas J. Kim, David H. Peng, Dana Duan, Don L. Gibbons, Mitsuo Yamauchi, Julia R. Jackson, Claude J. Le Saux, Cheresa Calhoun, Jay Peters, Rik Derynck, Bradley J. Backes, Harold A. Chapman
Journal: Journal of Clinical Investigation (2017)

TGF-β1 signaling is a critical driver of collagen accumulation and fibrotic disease but also a vital suppressor of inflammation and epithelial cell proliferation. The nature of this multifunctional cytokine has limited the development of global TGF-β1 signaling inhibitors as therapeutic agents. We conducted phenotypic screens for small molecules that inhibit TGF-β1–induced epithelial-mesenchymal transition without immediate TGF-β1 receptor (TβR) kinase inhibition. We identified trihydroxyphenolic compounds as potent blockers of TGF-β1 responses (IC50 ~50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis. Remarkably, the functional effects of trihydroxyphenolics required the presence of active lysyl oxidase–like 2 (LOXL2), thereby limiting effects to fibroblasts or cancer cells, the major LOXL2 producers. Mechanistic studies revealed that trihydroxyphenolics induce auto-oxidation of a LOXL2/3–specific lysine (K731) in a time-dependent reaction that irreversibly inhibits LOXL2 and converts the trihydrophenolic to a previously undescribed metabolite that directly inhibits TβRI kinase. Combined inhibition of LOXL2 and TβRI activities by trihydrophenolics resulted in potent blockade of pathological collagen accumulation in vivo without the toxicities associated with global inhibitors. These findings elucidate a therapeutic approach to attenuate fibrosis and the disease-promoting effects of tissue stiffness by specifically targeting TβRI kinase in LOXL2-expressing cells.
インプリンティング異常症:ヒストンメチルトランスフェラーゼG9aの標的化はインプリントされた遺伝子を活性化し,プラダー・ウィリー症候群マウスモデルの生存を改善する
Authors: Kim Yuna, Cao Xinyu, Jiang Yong‐hui, Lee Hyeong‐Min, Sciaky Noah, Roth Bryan L, Xiong Yan, Jin Jian, Hulbert Samuel W, Everitt Jeffrey I
Journal: Nature Medicine (2017)